Evidence map›Paper›PMID 39596014›Full record

ReviewInternational journal of molecular sciences2024

Extracellular Vesicles as Biomarkers of Pregnancy Complications.

Anastasiia K Popova, Elena S Vashukova, Roman A Illarionov, Anastasia R Maltseva, Olga V Pachuliia, Tatiana B Postnikova, Andrey S Glotov

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Therapeutic potential of extracellular vesicles for treating human pregnancy disorders.Extracellular vesicles and circulating nucleic acids · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anastasiia K PopovaDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.ORCID 0009-0008-3512-2557
Elena S VashukovaDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.
Roman A IllarionovDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.
Anastasia R MaltsevaDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.
Olga V PachuliiaDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.ORCID 0000-0003-4116-0222
Tatiana B PostnikovaDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.
Andrey S GlotovDepartment of Genomic Medicine, D.O. Ott Research Institute for Obstetrics, Gynecology, and Reproduction, St. Petersburg 199034, Russia.ORCID 0000-0002-7465-4504

Funding

Russian Science Foundation 19-75-20033-P
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are double-membrane vesicles that facilitate intercellular communication and play a pivotal role in both physiological and pathological processes. A substantial body of evidence suggests that EVs play a role in the pathogenesis of various pregnancy complications. Because EVs can be detected in the peripheral blood, they are potential biomarkers for the early diagnosis of pregnancy complications and foetal developmental disorders. The majority of studies have demonstrated a correlation between alterations in the concentration of EVs and changes in their contents and the occurrence of pregnancy complications. Despite the current limitations in establishing a clear link between these findings and the pathogenesis of the disease, as well as the lack of sufficient evidence to support their use in clinical practice, it is noteworthy to highlight the potential role of specific miRNAs carried by EVs in the development of pregnancy complications. These include miR-210 and miR-136-5p for pre-eclampsia and gestational diabetes mellitus, miR-155, miR-26b-5p, miR-181a-5p, miR-495 and miR-374c for pre-eclampsia and preterm birth. The following miRNAs have been identified as potential biomarkers for preterm birth and gestational diabetes mellitus: miR-197-3p and miR-520h, miR-1323, miR-342-3p, miR-132-3p, miR-182-3p, miR-517-3p, miR-222-3p, miR-16-5p and miR-126-3p. Additionally, miR-127-3p has been linked to foetal growth restriction and preterm birth. Nevertheless, it would be premature to propose that EVs can be employed as biomarkers for pregnancy complications. Further research and the accumulation of results obtained using the methods proposed in the MISEV2023 guidelines will enable a definitive conclusion to be reached.

Indexed as

BiomarkersExtracellular VesiclesMicroRNAsPregnancy ComplicationsDiabetes, GestationalFemaleHumansPre-EclampsiaPregnancyBiomarkersMicroRNAsbiomarkersextracellular vesiclespregnancypregnancy complications

Identifiers

PMID39596014
PMCPMC11594130

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.